Your browser doesn't support javascript.
loading
Treatment of walled-off necrosis using lumen-apposing metal stents versus plastic stents: a systematic review and meta-analysis of data from randomized trials.
Bang, Ji Young; Wilcox, Charles Melbern; Navaneethan, Udayakumar; Hawes, Robert Holbrook; Varadarajulu, Shyam.
Afiliação
  • Bang JY; Digestive Health Institute, Orlando Health, Orlando, United States.
  • Wilcox CM; Digestive Health Institute, Orlando Health, Orlando, United States.
  • Navaneethan U; Digestive Health Institute, Orlando Health, Orlando, United States.
  • Hawes RH; Digestive Health Institute, Orlando Health, Orlando, United States.
  • Varadarajulu S; Digestive Health Institute, Orlando Health, Orlando, United States.
Endoscopy ; 56(3): 184-195, 2024 Mar.
Article em En | MEDLINE | ID: mdl-37673106
ABSTRACT

BACKGROUND:

Walled-off necrosis (WON) is highly morbid disease most effectively managed by endoscopic drainage with lumen-apposing metal stents (LAMSs) or plastic stents, with or without necrosectomy. This meta-analysis compared the clinical outcomes of patients included in randomized trials treated using LAMSs or plastic stents.

METHODS:

The MEDLINE and EMBASE databases were searched to identify all data collected from randomized trials comparing LAMSs and plastic stents for the treatment of WON. The primary outcome measure was need for endoscopic necrosectomy.

RESULTS:

Three studies comprising 206 patients met inclusion criteria. Except for procedure duration, which was significantly shorter for LAMSs (standardized mean difference [SMD] -1.22, 95%CI -1.64 to -0.79), there was no significant difference in need for necrosectomy (38.5% vs. 41.2%; risk ratio [RR] 1.07, 95%CI 0.79-1.45), number of interventions (SMD -0.09, 95%CI -0.40 to 0.22), treatment success (90.7% vs. 94.5%; RR 0.96, 95%CI 0.87-1.06), recurrence (4.6% vs. 0.6%; RR 3.73, 95%CI 0.42-33.0), readmission (42.6% vs. 50.2%; RR 0.84, 95%CI 0.62-1.14), length of hospitalization (SMD -0.06, 95%CI -0.55 to 0.43), mortality (8.5% vs. 9.8%; RR 0.70, 95%CI 0.30-1.66), new-onset organ failure (10.6% vs. 14.6%; RR 0.72, 95%CI 0.16-3.32), bleeding (11.0% vs. 10.7%; RR 1.09, 95%CI 0.34-3.44), procedural adverse events (23.6% vs. 19.2%; RR 1.38, 95%CI 0.82-2.33), or overall costs (SMD -0.04, 95%CI -0.31 to 0.24) between LAMSs and plastic stents, respectively.

CONCLUSIONS:

Except for procedure duration, there is no significant difference in clinical outcomes for patients with WON treated using LAMSs or plastic stents.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plásticos / Pancreatite Necrosante Aguda Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Endoscopy Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Plásticos / Pancreatite Necrosante Aguda Tipo de estudo: Clinical_trials / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Endoscopy Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos